Abstract

The relationship between metabolism and methylation is considered to be an important aspect of cancer development and drug efficacy. However, it remains poorly defined how to apply this aspect to improve preclinical disease characterization and clinical treatment outcome. Using available molecular information from Kyoto Encyclopedia of Genes and Genomes (KEGG) and literature, we constructed a large-scale knowledge-based metabolic in silico model. For the purpose of model validation, we applied data from the Cancer Cell Line Encyclopedia (CCLE) to investigate computationally the impact of metabolism on chemotherapy efficacy. In our model, different metabolic components such as MAT2A, ATP6V0E1, NNMT involved in methionine cycle correlate with biologically measured chemotherapy outcome (IC50) that are in agreement with findings of independent studies. These proteins are potentially also involved in cellular methylation processes. In addition, several components such as 3,4-dihydoxymandelate, PAPSS2, UPP1 from metabolic pathways involved in the production of purine and pyrimidine correlate with IC50. This study clearly demonstrates that complex computational approaches can reflect findings of biological experiments. This demonstrates their high potential to grasp complex issues within systems medicine such as response prediction, biomarker identification using available data resources.

Highlights

  • Over the past decade, various studies have discovered a number of metabolic changes that promote or support cancer development [1, 2]

  • The simulation results for protein components of the model were subsequently used to calculate correlations with the IC50 of different drug treatment from various cancer cell lines taken from the treatment data of Cancer Cell Line Encyclopedia (CCLE) [31]

  • It is of interest to study how the MCPM reflects the mode of action determined through different properties of cancer metabolism [3, 19, 32,33,34]

Read more

Summary

Introduction

Various studies have discovered a number of metabolic changes that promote or support cancer development [1, 2]. Understanding the pathways and mechanisms of cancer metabolism holds promise for improving patient drug treatment [6, 7] In this regard, several recent studies provide evidence that serine metabolism is an essential energy source for cancer development, which make this serine-based metabolic pathway a potentially druggable target [8, 9]. A number of studies in the past decade have investigated the complex role of epigenetics in human cancer [10,11,12] Epigenetic regulations such as DNA methylation, histone modification, and nucleosome remodeling can influence diverse biological processes that are fundamental to the initiation and development of cancer [13]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call